Myeloproliforative Disorder
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants (MK3543-007)
- Details
ClinicalTrials.gov ID:
NCT06456346
Diagnosis Type:
NA
USOR Number:
- Address
,
P: